Professor | Ji Yanxiao | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Ji Yanxiao

Contact Information

jiyanxiao@whu.edu.cn

Language ability

Chinese, English

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2005-2009 Bachelor in Bioengineering: Chengdu University of Technology 2009-2015 PhD in Genetics: Wuhan University
Work Experience	2015-2017 Postdoctoral Researcher, Basic Medical College, Wuhan University 2017-2021 Assistant Researcher, Zhongnan Hospital of Wuhan University 2021-present Distinguished Researcher, Basic Medical College, Wuhan University

University/Lab Affiliation and Title

Wuhan University

Faculty

Basic Medical Sciences

Academic Background & Achievements

Work Experience

Areas of Focus	Post-translational modifications and metabolic disease mechanisms Antibody and small molecule drug development
Publications	A kinome screen reveals that Nemo-like Kinase is a key upstream regulator of hepatic gluconeogenesis, Ji YX et al., 2021 Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling, Wang J et al., 2020 Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation, Zhang L et al., 2020 Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes, Cheng X et al., 2020 F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice, Bai L et al., 2019 Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Fang J et al., 2019 The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis, Ji YX et al., 2018 Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Wang PX et al., 2017 The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling, Ji YX et al., 2016 Suppressor of IKKvarepsilon is an essential negative regulator of pathological cardiac hypertrophy, Deng KQ et al., 2016

Areas of Focus

Post-translational modifications and metabolic disease mechanisms
Antibody and small molecule drug development

Publications

A kinome screen reveals that Nemo-like Kinase is a key upstream regulator of hepatic gluconeogenesis, Ji YX et al., 2021
Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling, Wang J et al., 2020
Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation, Zhang L et al., 2020
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes, Cheng X et al., 2020
F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice, Bai L et al., 2019
Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, Fang J et al., 2019
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis, Ji YX et al., 2018
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Wang PX et al., 2017
The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling, Ji YX et al., 2016
Suppressor of IKKvarepsilon is an essential negative regulator of pathological cardiac hypertrophy, Deng KQ et al., 2016

Post-Translational Metabolic Diseases Mechanisms Protein Modifications Drug Development Antibodies Small Molecules Target-Based Research Therapeutics

Luman Wang - Fudan University

Cai-Hong Yun - Peking University

Dongcheng Wu - Wuhan University

View All

Personal Information